Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Operating Leases (2018 - 2025)

Summit Therapeutics' Operating Leases history spans 8 years, with the latest figure at $2.7 million for Q3 2025.

  • For Q3 2025, Operating Leases fell 35.63% year-over-year to $2.7 million; the TTM value through Sep 2025 reached $2.7 million, down 35.63%, while the annual FY2024 figure was $3.5 million, 4.95% up from the prior year.
  • Operating Leases reached $2.7 million in Q3 2025 per SMMT's latest filing, up from $2.4 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $5.8 million in Q1 2024 to a low of $351000.0 in Q1 2021.
  • Average Operating Leases over 5 years is $2.8 million, with a median of $2.8 million recorded in 2022.
  • Peak YoY movement for Operating Leases: soared 2154.67% in 2021, then tumbled 51.47% in 2025.
  • A 5-year view of Operating Leases shows it stood at $1.7 million in 2021, then skyrocketed by 63.39% to $2.8 million in 2022, then grew by 19.07% to $3.3 million in 2023, then increased by 4.95% to $3.5 million in 2024, then dropped by 21.58% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for SMMT's Operating Leases are $2.7 million (Q3 2025), $2.4 million (Q2 2025), and $2.9 million (Q1 2025).